deltatrials
Terminated PHASE3 INTERVENTIONAL 2-arm NCT02674958

Mobilization of Endothelial Progenitor Cells and Aspirin (TROPHIC 3)

Mobilization of Endothelial Progenitor Cells Following Alcohol Septal Ablation in Hypertrophic Obstructive Cardiomyopathy: Randomized Controlled Trial of Aspirin

Sponsor: Ottawa Heart Institute Research Corporation

Conditions Hypertrophic Obstructive Cardiomyopathy
Interventions Aspirin
Updated 8 times since 2017 Last updated: Jan 12, 2023 Started: May 31, 2016 Primary completion: Apr 1, 2022 Completion: Apr 1, 2022
This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

Terminated

Covid-19 pandemic

Other terminated trials from Ottawa Heart Institute Research Corporation

More terminations from Ottawa Heart Institute Research Corporation

Other Hypertrophic Obstructive Cardiomyopathy trials with similar outcome

Browse all Hypertrophic Obstructive Cardiomyopathy trials

Listed as NCT02674958, this PHASE3 trial focuses on Hypertrophic Obstructive Cardiomyopathy and remains terminated or withdrawn. Sponsored by Ottawa Heart Institute Research Corporation, it has been updated 8 times since 2016, reflecting limited change activity. This study adds to the evidence base for this therapeutic area through structured, versioned documentation.

Status Flow

~Jan 2017 – ~Jun 2018 · 17 months · monthly snapshotRecruiting~Jun 2018 – ~Jul 2019 · 13 months · monthly snapshotRecruiting~Jul 2019 – ~Jan 2021 · 18 months · monthly snapshotRecruiting~Jan 2021 – ~May 2022 · 16 months · monthly snapshotRecruiting~May 2022 – ~Feb 2023 · 9 months · monthly snapshotRecruiting~Feb 2023 – ~Jul 2024 · 17 months · monthly snapshotTerminated~Jul 2024 – ~Sep 2024 · 2 months · monthly snapshotTerminated~Sep 2024 – present · 22 months · monthly snapshotTerminated

Change History

8 versions recorded

  1. Sep 2024 — Present [monthly]

    Terminated PHASE3

  2. Jul 2024 — Sep 2024 [monthly]

    Terminated PHASE3

  3. Feb 2023 — Jul 2024 [monthly]

    Terminated PHASE3

    Status: Recruiting → Terminated

  4. May 2022 — Feb 2023 [monthly]

    Recruiting PHASE3

  5. Jan 2021 — May 2022 [monthly]

    Recruiting PHASE3

▶ Show 3 earlier versions

  1. Jul 2019 — Jan 2021 [monthly]

    Recruiting PHASE3

  2. Jun 2018 — Jul 2019 [monthly]

    Recruiting PHASE3

  3. Jan 2017 — Jun 2018 [monthly]

    Recruiting PHASE3

    First recorded

May 2016

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:
  • Ottawa Heart Institute Research Corporation
Data source: Ottawa Heart Institute Research Corporation

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations